Amgen’s low-dose Kras curveball
The company reveals that it will test a low dose of sotorasib, a move apparently requested by the US FDA.
Valneva joins the phase 3 Covid-19 vaccine club
Meanwhile, Ocugen hopes that Covaxin's India data will be enough for US approval.
Novartis’s nuclear vision starts to take shape
A radioligand acquired as part of a $2.1bn deal – and which the sellside believes to be Novartis’s most valuable R&D asset – hits in phase III.
